<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amobarbital: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amobarbital: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amobarbital: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8647" href="/d/html/8647.html" rel="external">see "Amobarbital: Drug information"</a> and <a class="drug drug_patient" data-topicid="11076" href="/d/html/11076.html" rel="external">see "Amobarbital: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F134276"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Amytal Sodium</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F997927"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Barbiturate</span>;</li>
<li>
<span class="list-set-name">Barbiturate</span>;</li>
<li>
<span class="list-set-name">General Anesthetic</span>;</li>
<li>
<span class="list-set-name">Hypnotic</span>;</li>
<li>
<span class="list-set-name">Sedative</span></li></ul></div>
<div class="block dop drugH1Div" id="F134291"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosage should be individualized with consideration of patient's age, weight, and medical condition. Although described in the manufacturer labeling, amobarbital is not recommended for use in the management of pediatric insomnia, procedural sedation, or other types of nonprocedural sedation (eg, sedation in mechanically ventilated patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27139328','lexi-content-ref-26378738','lexi-content-ref-25602358','lexi-content-ref-16517277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27139328','lexi-content-ref-26378738','lexi-content-ref-25602358','lexi-content-ref-16517277'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="08e87b36-08df-4d6d-bc69-f4531114dc95">Sedation, preoperative or procedural</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation, preoperative or procedural:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: IM (preferred), IV: Usual recommendation: 2 to 3 mg/kg/dose; maximum dose: 500 mg/dose; dosing based on generally recognized expert recommendations; published pediatric trial data is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.1'])">Ref</a></span>). The manufacturer describes the ordinary dose range in children 6 to 12 years as 65 to 500 mg and specific dosing recommendations based on patient size are not available; however, in several instances, this may exceed expert weight-based recommendations; if using manufacturer dosing, initiate therapy at the lower end of the range and titrate the dose accordingly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intracarotid amobarbital procedure (Wada test):</i> Limited data available; dosing regimens variable: Children ≥6 years and Adolescents: Intra-arterial: 75 to 125 mg/dose; typically administered through femoral arterial catheter; consult institution-specific protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9337141','lexi-content-ref-19208439','lexi-content-ref-7923234','lexi-content-ref-17704003','lexi-content-ref-8223420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9337141','lexi-content-ref-19208439','lexi-content-ref-7923234','lexi-content-ref-17704003','lexi-content-ref-8223420'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064758"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; dosing should be reduced; specific recommendations not available.</p></div>
<div class="block dohp drugH1Div" id="F51064759"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; dosing should be reduced; specific recommendations not available; drug is contraindicated in patients with marked hepatic impairment; avoid use in patients with premonitory signs of hepatic coma.</p></div>
<div class="block doa drugH1Div" id="F134280"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8647" href="/d/html/8647.html" rel="external">see "Amobarbital: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6583abf7-75d4-4cf0-8d02-81e4c42a6c4a">Wada test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wada test (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to the adverse effects associated with intra-carotid amobarbital and questionable reliability and validity, other less invasive tests (eg, functional MRI) may be recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190900'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intra-carotid:</b> 60 to 200 mg (usual dose: 125 mg) over 2 to 5 seconds via percutaneous transfemoral catheter; after 30 to 45 minutes has elapsed since completion of first injection, may repeat dose for evaluation of contralateral hemisphere (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9337141','lexi-content-ref-21325100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9337141','lexi-content-ref-21325100'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990518"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; reduced doses are recommended.</p></div>
<div class="block doha drugH1Div" id="F50987824"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; reduced doses are recommended. Do not administer to patients with hepatic encephalopathy.</p></div>
<div class="block adr drugH1Div" id="F134246"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class (barbiturates) and may not be specifically reported for amobarbital.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, hypotension, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Megaloblastic anemia (following chronic phenobarbital use)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking, agitation, anxiety, ataxia, central nervous system depression, confusion, dizziness, drowsiness, hallucination, headache, insomnia, nervousness, nightmares, psychiatric disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, atelectasis (postoperative), hypoventilation</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F134261"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to barbiturates or any component of the formulation; history of manifest or latent porphyria; marked liver function impairment; marked respiratory disease in which dyspnea or obstruction is evident.</p></div>
<div class="block war drugH1Div" id="F134243"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Paradoxical responses: May cause paradoxical excitement, particularly in patients with acute or chronic pain.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Use with caution in patients with adrenal insufficiency. Systemic effects of exogenous and endogenous corticosteroids may be diminished by amobarbital.</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Use with caution, if at all, in patients with depression or suicidal tendencies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug abuse: Use with caution, if at all, in patients with a history of substance or alcohol use disorder; potential for drug dependency exists. Tolerance and psychological and physical dependence may occur with prolonged use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, decreased dosage may be needed. Do not administer to patients with hepatic encephalopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; decreased dosage may be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with respiratory disease; may cause respiratory depression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Avoid use in older adults; may react to barbiturates with marked excitement, depression, and confusion (Beers Criteria [AGS 2019]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Barbiturates repeatedly produce excitement rather than depression in some patients, particularly children. Neonates may experience withdrawal symptoms with chronic maternal use; monitor closely. In pediatric patients, barbiturates may produce paradoxical excitement.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alkaline solution: Solution for injection is highly alkaline and extravasation may cause local tissue damage with subsequent necrosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Rapid IV administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with a fall in blood pressure; avoid perivascular extravasation or intra-arterial injection; discontinue if patient complains of pain in the limb. Restrict use of IV administration to conditions in which other routes are not feasible, if patient is unconscious (eg, cerebral hemorrhage, eclampsia, or status epilepticus) or patient resists (eg, delirium), or because prompt action is imperative.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Abrupt cessation may precipitate withdrawal, including delirium and convulsions (some fatal); withdraw gradually.</p></div>
<div class="block foc drugH1Div" id="F134255"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amytal Sodium: 500 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F134239"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322985"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Amytal Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $879.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block csi drugH1Div" id="F134302"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-II</p></div>
<div class="block admp drugH1Div" id="F52612228"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Following reconstitution, dose must be administered within 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">IM (preferred): Administer deeply into a large muscle. Do not use more than 5 mL at any single site (may cause tissue damage).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Use only when IM administration is not feasible. Administer by slow IV injection (maximum rate: 50 mg/minute in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Intracarotid: Wada test: Administer dose over 2 to 5 seconds via percutaneous transfemoral catheter into the internal carotid artery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9337141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9337141'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F134258"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer deeply into a large muscle. Do not use more than 5 mL (irrespective of concentration) at any single site (may cause tissue damage). Use 20% solution to facilitate larger doses. Superficial IM or subcutaneous injections may be painful and produce sterile abscesses or sloughs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Use only when IM administration is not feasible. Administer by slow IV injection (maximum rate of infusion: 50 mg/minute in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-carotid</b> (off-label route): Wada test (off-label use): Administer dose over 2 to 5 seconds via percutaneous transfemoral catheter into the internal carotid artery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9337141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9337141'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F134270"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 15°C to 30°C (59°F to 86°F). Following reconstitution, solution should be used within 30 minutes.</p></div>
<div class="block usep drugH1Div" id="F53565380"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Provide sedation preoperatively; short-term treatment of insomnia (FDA approved in ages ≥6 years and adults); has also been used for the intracarotid amobarbital procedure (Wada test). <b>Note:</b> Although described in the manufacturer labeling, amobarbital is not recommended for use in the management of pediatric insomnia, procedural sedation, or other types of nonprocedural sedation (eg, sedation in mechanically ventilated patients) (Barnes 2016; Brown 2016; Curley 2015; Krauss 2006).</p></div>
<div class="block mst drugH1Div" id="F13930080"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Amobarbital is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its high rate of physical dependence, tolerance to sleep benefits, and increased risk of overdose at low dosages (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F134296"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F134248"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Barbiturates may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Barbiturates may enhance the nephrotoxic effect of Methoxyflurane. Barbiturates may increase the metabolism of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the CNS depressant effect of Barbiturates. Mianserin may diminish the therapeutic effect of Barbiturates. Barbiturates may decrease the serum concentration of Mianserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.  Management: Monitor for decreased efficacy of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Tricyclic antidepressant dose adjustments are likely required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.  Management: Monitor INR more closely. Anticoagulant dose increases of 30% to 60%  may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F134263"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Barbiturates cross the placenta and distribute in fetal tissue. Teratogenic effects have been reported with first trimester exposure. Exposure during the third trimester may lead to symptoms of acute withdrawal following delivery; symptoms may be delayed up to 14 days.</p></div>
<div class="block mopp drugH1Div" id="F53565376"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs should be monitored during injection and for several hours after administration. If using IV, monitor patency of IV access; extravasation may cause local tissue damage. Monitor hematologic, renal, and hepatic function with prolonged therapy.</p></div>
<div class="block rerp drugH1Div" id="F53565316"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic: 1 to 5 mcg/mL (SI: 4.4 to 22.1 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">Toxic: &gt;10 mcg/mL (SI: &gt;44.2 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">Lethal: &gt;50 mcg/mL (SI: &gt;221 micromole/L).</p></div>
<div class="block pha drugH1Div" id="F134242"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">An intermediate-acting barbiturate; barbiturates depress the sensory cortex, decrease motor activity, and alter cerebellar function producing drowsiness, sedation, and hypnosis.</p></div>
<div class="block phk drugH1Div" id="F134260"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Rapid, within minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration of action: Variable </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily hepatic via microsomal enzymes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 16 to 40 hours (mean: 25 hours) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Maximum effect: Hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as metabolites, negligible amounts excreted unchanged in urine); feces (metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F134265"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Amytal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Amytal Sodium</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amybal | Isomytal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amytal Sodium</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amytal Sodium</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Isomyl natrium</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Amytal Sodium</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Isomytal Sodium</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHSP.1">
<a name="ASHSP.1"></a>American Society of Health-System Pharmacists. <i>AHF Drug Information 2015</i>. 2-15.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9337141">
<a name="9337141"></a>Acharya J, Dudley D. Use of intracarotid amobarbital procedure in the evaluation of memory. <i>J Clin Neurophysiol</i>. 1997;14(4):311-325.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/9337141 /pubmed" id="9337141 " target="_blank">9337141 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amytal.1">
<a name="Amytal.1"></a>Amytal sodium (amobarbital) [prescribing information]. North Charleston, SC: Alcami Carolinas Corp; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27139328">
<a name="27139328"></a>Barnes S, Yaster M, Kudchadkar SR. Pediatric sedation management. <i>Pediatr Rev</i>. 2016;37(5):203-212. doi:10.1542/pir.2014-0116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/27139328/pubmed" id="27139328" target="_blank">27139328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26378738">
<a name="26378738"></a>Brown KM, Malow BA. Pediatric insomnia. <i>Chest</i>. 2016;149(5):1332-1339. doi:10.1378/chest.15-0605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/26378738/pubmed" id="26378738" target="_blank">26378738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19208439">
<a name="19208439"></a>Burns TG, Lee GP, McCormick ML, Pettoni AN, Flamini JR, Cohen M. Carbonic anhydrase-inhibiting medications and the intracarotid amobarbital procedure in children. <i>Epilepsy Behav</i>. 2009;15(2):240-244.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/19208439/pubmed" id="19208439" target="_blank">19208439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25602358">
<a name="25602358"></a>Curley MA, Wypij D, Watson RS, et al. Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure: a randomized clinical trial. <i>JAMA</i>. 2015;313(4):379-389. doi:10.1001/jama.2014.18399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/25602358/pubmed" id="25602358" target="_blank">25602358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7923234">
<a name="7923234"></a>Hinz AC, Berger MS, Ojemann GA, Dodrill C. The utility of the intracarotid Amytal procedure in determining hemispheric speech lateralization in pediatric epilepsy patients undergoing surgery. <i>Childs Nerv Syst</i>. 1994;10(4):239-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/7923234/pubmed" id="7923234" target="_blank">7923234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17704003">
<a name="17704003"></a>Kim JH, Joo EY, Han SJ, Cho JW, Lee JH, Seo DW, Hong SB. Can pentobarbital replace amobarbital in the Wada test? <i>Epilepsy Behav</i>. 2007;11(3):378-383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/17704003/pubmed" id="17704003" target="_blank">17704003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16517277">
<a name="16517277"></a>Krauss B, Green SM. Procedural sedation and analgesia in children. <i>Lancet</i>. 2006;367(9512):766-780. doi:10.1016/S0140-6736(06)68230-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/16517277/pubmed" id="16517277" target="_blank">16517277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McEvoy.1">
<a name="McEvoy.1"></a>McEvoy GK, Litvak K, Welsh O, et al, eds. <i>AHFS Drug Information</i> 1993. Bethesda, MD: American Society of Health-System Pharmacists Inc; 1993.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1">
<a name="Nelson.1"></a>Nelson WE, Behrman RE, Kliegman RM, Arvin AM, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21325100">
<a name="21325100"></a>Patel A, Wordell C, Szarlej. Alternatives to Sodium Amobarbital in the Wada Test. <i>Ann Pharmacother</i>. 2011;45(3):395-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/21325100/pubmed" id="21325100" target="_blank">21325100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27998379">
<a name="27998379"></a>Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. <i>J Clin Sleep Med</i>. 2017;13(2):307-349. doi:10.5664/jcsm.6470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/27998379/pubmed" id="27998379" target="_blank">27998379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190900">
<a name="21190900"></a>Sharan A, Ooi YC, Langfitt J, Sperling MR. Intracarotid amobarbital procedure for epilepsy surgery. <i>Epilepsy and Behav</i>. 2011;20(2):209-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/21190900/pubmed" id="21190900" target="_blank">21190900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8223420">
<a name="8223420"></a>Szabó CA and Wyllie E, "Intracarotid Amobarbital Testing for Language and Memory Dominance in Children," <i>Epilepsy Res</i>, 1993, 15(3):239-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amobarbital-pediatric-drug-information/abstract-text/8223420/pubmed" id="8223420" target="_blank">8223420</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13391 Version 273.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
